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INTRODUCTION: The functional evaluation has become increasingly important in the understanding and
management of patients with interstitial lung diseases. The cardiopulmonary exercise test and the six-minute
walk test (6MWT), through their isolated variables, have been used to do this evaluation, with some limitations.
OBJECTIVES: We proposed a new composite index (desaturation distance ratio using continuous peripheral oxygen
saturation (SpO2) and the distance walked as a more reliable tool for doing a functional evaluation of these
patients.
METHODS: 6MWT was performed by interstitial lung diseases patients and controls. Analyzed parameters were
walked distance and desaturation area (DAO2), obtained by taking the difference between maximal SpO2 possible
(100%) and patient’s SpO2 every 2 seconds. desaturation distance ratio was calculated using the ratio between
DAO2 and distance walked.
RESULTS: Forty-nine interstitial lung diseases patients and 11 control subjects completed the protocol. The mean
(SD) age was 60 (12) years and 65 (9) years, respectively (p:NS). Data obtained from 6MWT showed a significant
statistical difference between interstitial lung diseases patients and controls: mean walked distance (430 and 602
meters, respectively); SpO2 minimal maintained at least 10 seconds - SpO2 min (85% and 94%, respectively), and
median desaturation distance ratio (10 and 2.5, respectively). A correlation analysis, considering interstitial lung
diseases patients, revealed the best correlation between desaturation distance ratio and DLco (r = - 0.72; p,0.001),
being the correlation between SpO2 min and DLco of 0.61 (p,0.001) and among walked distance and DLco of 0.58
(p,0.05).
CONCLUSION: Desaturation distance ratio is a promising concept and a more reliable physiologic tool to assess
pulmonary diseases characterized by involvement of the alveolar-capillary membrane, such as interstitial lung
diseases.
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INTRODUCTION
The functional capacity evaluation has become increas-
ingly important in understanding and managing patients
with chronic lung diseases.1-3 The cardiopulmonary exercise
test (CPET) using a cycle ergometer or treadmill protocols
have been used in patients with restrictive and obstructive
lung diseases, and they provide a good correlation between
survival and functional capacity among individuals in these
groups.1,2,4-6
In patients with interstitial lung diseases (ILD), especially
those with diffuse fibrotic lung diseases, these protocols
typically show a fall in peripheral oxygen saturation (SpO2)
during exercise.7,8 However, some patients may be unfami-
liar with this type of assessment, it may not be possible to
extrapolate their daily life activities from its results, it may
have limited reproducibility in patients with idiopathic
pulmonary fibrosis (IPF), and it requires specific equipment
with a high cost.1,5,9 Recently, researchers observed that
some patients in rehabilitation programs did not have
oxygen desaturation during CPET but had such an event
during walking tests.6
The six-minute walk test (6MWT) is a simple, efficient,
and low-cost tool used to evaluate the performance of
individuals during submaximal exercise, and it can be safely
applied in patients with heart and/or advanced lung
disease.1,10-12
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Despite the controversy regarding the use of walked
distance or oxygen desaturation for better correlation with
pulmonary function or survival data, recent studies have
demonstrated the efficacy of using the 6MWT to evaluate the
effectiveness of therapy in patients with interstitial lung
diseases, pulmonary rehabilitation follow-up, marking cri-
teria for transplantation and indication for supplementary
oxygen, concluding that it offers a good correlation with the
functional capacity and survival of these patients.1-4,9,10,13
Desaturation during 6MWT is associated with higher
mortality and has a good correlation with variables of
pulmonary function, such as forced vital capacity (FVC),
diffusion of carbon monoxide (DLco), total lung capacity
(TLC), and SpO2 at rest in patients with interstitial lung
diseases.4,5,13 Nevertheless, some researchers have con-
cluded that the distance covered in 6MWT has a stronger
correlation with severity and survival of patients with IPF
than SpO2 alone.
10,14 Eaton and colleagues showed that the
covered distance in 6MWT is highly reproducible and has a
better prognostic value than SpO2 due to its large variability
and because of the fact that it may not be a reliable
parameter in fibrotic idiopathic interstitial pneumonia.9
Lettieri and colleagues proposed an index that includes
both parameters: walked distance and degree of desatura-
tion during 6MWT.1 Using the product of the lowest SpO2
identified by the distance in meters (distance - saturation
product – DSP), they developed a composite index with
higher sensitivity and specificity to determine 12-month
survival in IPF patients compared to pulmonary function
data or isolated variables of 6MWT. Despite the fact that this
index includes these two parameters, it is limited to a
specific minimum value of SpO2 during the 6MWT, which
does not reflect the entire oxygen saturation during the test,
so it may underestimate the functional condition of the
patient.1
The purpose of this study was to create a new composite
index based on the 6MWT, using oximetry (continuous
peripheral oxygen saturation registered every 2 seconds
during the test) and the distance walked, in order to develop
a more reliable tool for functional assessment of patients
with interstitial lung diseases.
MATERIALS AND METHODS
Study design
We developed a transversal study and invited patients to
participate during their regular visits in our Interstitial
Pulmonary Outpatient Division. If the patient filled in all
inclusion criteria noted below (evaluated through medical
records review and physical examination during the visit)
he or she was invited to sign the free informed consent form
approved by the hospital ethics committee.
All patients included in the study needed to be able to
maintain peripheral resting saturation in room air (SpO2)
$ 88% and present no clinical signs of exacerbation.
Subjects
Fifty-one patients were assessed during their visits to
the Interstitial Pulmonary Outpatient Division of the
University of Sao Paulo Medical School. Twenty-five of
them had been diagnosed as having idiopathic pulmonary
fibrosis (IPF), 6 patients had chronic hypersensitivity
pneumonitis (CHP), 5 patients had centrilobular fibrosis
secondary to gastroesophageal reflux disease (GERD), and
15 patients received the diagnosis of lymphangioleiomyo-
matosis (LAM).15,16
Two of the IPF patients were not able to sustain room air
SpO2 $ 88% at rest. Therefore, 49 patients (23 IPF patients)
were recruited to be a part of this study.
The diagnosis criteria for IPF was based on American
Thoracic Society / European Respiratory Society (ATS/ERS)
guidelines. The CHP diagnosis was established in indivi-
duals exposed to a known offending antigen who exhibited
a relationship between symptoms and exposure, and there
were compatible pulmonary tomographic findings, and/or
the diagnosis was proven by a biopsy that excluded other
causes.17-19
The definition of GERD-related centrilobular fibrosis is
the combination of GERD-related symptoms (heartburn,
regurgitation, and dysphagia), compatible tomographic
features, clinical improvement after specific anti-reflux
therapy, and/or proven by a biopsy that excluded other
causes. Patients who had biopsy presented a pattern
compatible to centrilobular fibrosis (CLF).15,20,21
Lymphangioleiomyomatosis diagnosis was established
by the presence of pulmonary cystic lesions, combined or
not with angiomyolipomas and with typical features found
in a lung biopsy, such as smooth muscle cell positive anti-
actin antibody and positive antibody human melanoma
black (HMB45) in an immunohistochemistry study.22
A control group was made up of 11 healthy volunteers
with no history of tobacco use.
Measurements
Demographic data were recorded before the pulmonary
function tests were performed.
The six-minute walk test (6MWT) was carried out by a
trained technician, according to ATS guidelines, and it was
symptom-limited. Analyzed parameters were the walked
distance (in meters), SpO2 minimum maintained at least 10
seconds, and difference between basal saturation (at rest)
and the minimal one achieved in the test (SpO2 basal – SpO2
min).12,23
We created a new index named the desaturation -
distance ratio (DDR) based on a physiologic and a holistic
interpretation of 6MWT, considering that desaturation and
walked distance are equally important variables for pul-
monary functional assessment.
During the 6MWT that lasted 360 seconds, the patient
used the pulse oxymeter holter Nonin WristOxH 3100
(Plymouth, MN, USA) to record SpO2 and heart frequency
every 2 seconds. Data obtained during the 6MWT were
entered into a computer program, nVISIONH software
(Plymouth, MN, USA) and then exported to an EXCEL
worksheet. Then, each recorded SpO2 was subtracted from
100% (maximal SpO2) and plotted on a graph that showed
the desaturation area (DAO2) (gray area, Figure 1).
Following that, the DDR index was obtained using the ratio
between the desaturation area and the distance walked (see
an example in Figure 1). Patients who presented the worst
performance during 6MWT, with a low distance walked
and extensive periods of desaturation, presented a high
DDR index value.
A complete pulmonary function test (PFT) was performed
at the Laboratory of Pulmonary Physiology, Hospital das
Clinicas, within a period no longer than three days after
6MWT, using a whole-body plethysmograph of the Elite
Series Medgraphics H (Saint Paul, MN, USA). The values
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measured were forced vital capacity (FVC), forced expira-
tory volume in one second (FEV1), FEV1/FVC ratio,
inspiratory capacity (IC), total lung capacity (TLC), residual
volume (RV), and carbon monoxide diffusion capacity
(DLco). PFT was held to levels that met the recommenda-
tions of the reference values used for spirometry established
by Pereira and colleagues. For lung volumes and DLco, the
reference values were those recommended by Neder and
associates.24,25,26
The assessment of dyspnea was performed using the Borg
score, obtained by using a visual analogue scale, which
evaluates the intensity of dyspnea by quantifying the effort
during the exercise, using a range that varies from 0 to 10
points, where 0 is the absence of symptoms and 10 the worst
feeling of dyspnea or fatigue.20
Statistical analysis
Parametric variables were compared using Student’s t
test, and the Pearson coefficient was used to establish
correlations. The Mann-Whitney and Spearman coefficients
were used for non-parametric variables. All data were two-
tailed, and p values of less than 0.05 were assumed to
represent statistical significance. We used the software
package SPSS 15.0 (SPSS, Inc., Chicago, IL, USA) to perform
statistical analysis.
RESULTS
Forty-nine ILD patients and 11 control subjects completed
the protocol. The mean (SD) age was 60 (12) years in the first
group and 65 (9) years in the second one. Nineteen ILD
patients (39%) were ex-smokers. PFT analysis revealed
restrictive pattern in ILD patients, with a moderate
reduction in DLco (46% of predicted). Control patients
presented normal pulmonary functional parameters
(Table 1).
Data obtained from 6MWT showed significant statistical
differences between ILD patients and controls, with
emphasis on the mean walked distance (430 and 602 meters,
respectively) and the median difference between SpO2 basal
and SpO2 minimal (sustained for at least 10 s) during the
test, resulting in a 10-point drop in the first group and only 3
points in the control group. The median DDR was higher
among ILD patients (10) than in controls (2.5), due to the
Figure 1 - Desaturation - Distance Ratio (DDR): calculated using the ratio between DAO2 [gray area - obtained by subtraction between
each recorded SpO2 at every 2 seconds from 100% (maximal SpO2 )] and the distance walked.
Abbreviations: DAO2: desaturation area; SpO2: peripheral oxygen saturation
Table 1 - Demographic and functional parameters in ILD patients and controls.
ILD
CONTROLS (N = 11) TOTAL (N = 49)¤ IPF (N = 23) LAM (N = 15) CHP (N = 6) CLF (5)
Age years (SD) 65 (9) 60 (12)* 68 (9) 47 (7) 63 (11) 58 (11)
Sex (M / F) 9 / 2 24 / 25 17/6 0/15 2/4 4/1
Ex- smokers 0 / 11 19 / 49 15/23 3/15 4/6 1/5
FVC % (SD) 103 (11) 76 (16){ 72 (24) 89 (13) 70 (22) 74 (18)
FEV1 % (SD) 106 (11) 75 (18){ 79 (26) 71 (24) 76 (21) 81 (19)
TLC % (SD) 98 (11) 80 (19){ 74 (26) 98 (13) 72 (17) 73 (19)
DLco % (SD) 103 (21) 46 (16){ 39 (16) 55 (18) 46 (12) 56 (12)
ILD – interstitial lung disease; IPF – interstitial pulmonary fibrosis; LAM – lymphangioleiomyomatosis; CHP – chronic hypersensitivity pneumonitis; CLF –
centrilobular fibrosis; SD - Standard deviation; FVC % - predicted forced vital capacity; FEV1 % - predicted forced expiratory volume in the first second; TLC
% - predicted total lung capacity; DLco % - predicted diffusion capacity for carbon monoxide
¤t test between controls and all 49 ILD patients
*p value not significant {p , 0,05
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high desaturation and reduced walk distance observed in
those individuals (p,0.05) (Table 2).
Correlation analysis revealed significant and strong
correlation between DDR and predicted DLco (Figure 2).
The correlations between walked distance, SpO2 min, and
the difference (SpO2 basal – SpO2 min) demonstrated a
lower correspondence with DLco (Table 3). There was no
correlation between DDR or other 6MWT variables with
lung volumes (TLC and RV) (data not shown).
DISCUSSION
Many researchers have employed functional evaluations
using submaximal testing of patients with respiratory
diseases, such as chronic obstructive pulmonary disease
(COPD), pulmonary hypertension (PH), and interstitial lung
disease (ILD). In particular, the 6MWT has been widely
used.
Interstitial lung diseases, especially idiopathic pulmonary
fibrosis (IPF), are associated with high mortality and a
progressive decrease in exercise capacity.17 There is grow-
ing interest in diagnostic and prognostic methods in this
population in order to improve understanding and manage-
ment and provide better quality of life for these patients.
Table 2 - Six-minute walk test parameters in ILD patients and controls.
ILD
CONTROLS (N = 11) TOTAL (N = 49)¤ IPF (N = 23) LAM (N = 15) CHP (N = 6) CLF (5)
Distance (SD) 602 m (95) 430 m (122){ 373 m (114) 480m (116) 484 m (117) 474 m (87)
SpO2 basal % (SD) 96.5 (2) 95 (2)
* 94 (3) 95 (3) 95 (2) 96 (1)
SpO2 min % (SD) 94 (2) 85 (8)
{ 82 (7) 87 (10) 86 (5) 86 (4)
SpO2 basal - min (IQ) 3 (2 – 4) 10 (6 - 13)
{ 10 (9 - 15) 5 (2 - 11) 9 (6 - 11) 10 (6 - 12)
DDR (IQ) 2.5 (2 – 4.5) 10 (6 - 17){ 11 (9 - 23) 6 (4 - 12) 8 (6 - 10) 8 (6 - 8)
SD - Standard deviation; IQ – interquartile; Distance in meters; DDR - desaturation distance ratio; SpO2 basal % - peripheral oxygen saturation at rest; SpO2
min % - minimal sustained SpO2 during $ 10 seconds
¤Comparison between controls and all 49 ILD patients
*p value not significant {p , 0,05
Figure 2 - Correlation between DLco% and DDR in ILD patients.
Table 3 - Correlations between six-minute walk test
parameters and functional variables in ILD patients.
DD Ratio{ Distance* SpO2 min %* SpO2 basal - min
{
DLco % r = - 0.72 r = 0.58 r = 0.61 r = - 0.67
p , 0.001 p , 0.001 p , 0.001 p , 0.001
FVC % r = - 0.46 r = 0.33 r = 0.43 r = - 0.50
p = 0.001 p = 0.02 p = 0.002 p , 0.001
FEV1 % r = - 0.52 r = 0.25 r = 0.59 r = - 0.60
p , 0.001 p = 0.08 p , 0.001 p , 0.001
Distance in meters; DD Ratio - desaturation distance ratio; SpO2 min % -
minimal sustained peripheral oxygen saturation during $ 10 seconds;
SpO2 basal % - peripheral oxygen saturation at rest
*Pearson {Spearman
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Protocols using a treadmill or cycle ergometer have been
employed to assess the functional capacity of the population
with ILD, but these tests may be unfamiliar to patients and
require sophisticated and expensive equipment.1,5,9 The
6MWT is a simple tool with a low cost, and it is easily
applied in functional evaluation of patients with ILD, but
there is a disagreement in the literature about which is the
best 6MWT parameter (walked distance or decrease in
SpO2) to assess functional capacity, severity, or mortality in
this population.2,4,9,10,13
In this study, we created a composite index - DDR index -
that includes the two main variables obtained in 6MWT, the
distance walked and the decrease in SpO2 evaluated at
regular intervals during the 360-second test. We hypothe-
sized that the incorporation of these two main variables in a
unique index may help researchers evaluate one of the main
features of ILD, a disturbance in gas exchange that worsens
during exercise.26,27 In this population, exercise leads to an
increase in the alveolar-arterial O2 gradient concomitant
with a decrease in peripheral partial oxygen pressure (PaO2)
and peripheral oxygen saturation (SpO2), secondary to
multiple changes, especially in ventilation / perfusion
mismatch and a diffusion limitation in the alveolar capillary
membrane.26,27
According to Eaton and colleagues, walked distance
showed less variability and better correlation with DLco
and VO2 max than SpO2.
9 However, in a study done by
Lama et al, patients who presented a decrease in SpO2
during a 6MWT, equal or below 88%, exhibited significantly
lower values of FVC and DLco, and the decrease in
saturation (SpO2 basal – lowest saturation) was a significant
predictor of mortality, showing that for each percentage
decrease in saturation, mortality increased 23%.4
The divergence in these results may be due to the fact that
distance is highly dependent on patient efforts. Limited
efforts may lead to a smaller distance, preventing the
development of hypoxia. However, hypoxia can promote
dyspnea and reduce the distance covered. A combination of
these two parameters may minimize the impact of this effort
factor.
We demonstrated that DDR had a strong and significant
correlation with DLco but a weaker correlation with FVC
and FEV1 (Table 3). Full oxymetry, measured every 2
seconds, may more accurately reflect the diffusion capacity
of the alveolar – capillary membrane, which is reduced in
patients with ILD due to impaired gas exchange (reflected
by DLco).1,4,10,13
The strong correlation of DDR with DLco but not with
FVC or with other lung volumes may be explained by the
following factors. In the initial phases of ILD, decline in
DLco may precede abnormalities in lung volume.17 Many
patients in our sample were ex-smokers with superimposed
COPD, and, in this context, combined pulmonary fibrosis
and emphysema can lead to preserved or mildly reduced
lung volumes despite the significant decrease in DLCO.
28,29
In patients with LAM, there is also airway flow obstruction
caused by compression of the airways by smooth cell
proliferation or loss of lung elastic coil, leading to an
increase in lung volumes.30
We concluded that the combination of the desaturation
area and distance walked in a six-minute walk test (DDR
index) is a promising concept and a more reliable
physiologic tool to assess pulmonary diseases characterized
by involvement of the alveolar-capillary membrane, such as
ILD, and other pulmonary disorders like pulmonary
emphysema. Further studies are necessary to determine
the role of DDR in predicting mortality, disease progression,
and response to treatment in this subset of patients.
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